Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Safety of fondaparinux to prevent venous thromboembolism in Japanese patients undergoing colorectal cancer surgery: a multicenter study.

Hata T, Yasui M, Murata K, Okuyama M, Ohue M, Ikeda M, Ueshima S, Kitani K, Hasegawa J, Tamagawa H, Fujii M, Ohkawa A, Kato T, Morita S, Fukuzaki T, Mizushima T, Sekimoto M, Nezu R, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO)..

Surg Today. 2014 Nov;44(11):2116-23. doi: 10.1007/s00595-014-0911-7.

2.
3.

Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.

Donath L, Lützner J, Werth S, Kuhlisch E, Hartmann A, Günther KP, Weiss N, Beyer-Westendorf J.

Br J Clin Pharmacol. 2012 Dec;74(6):947-58. doi: 10.1111/j.1365-2125.2012.04302.x.

4.

The efficacy of fondaparinux for the prophylaxis of venous thromboembolism after resection for colorectal cancer.

Tsutsumi S, Yajima R, Tabe Y, Takaaki T, Fujii F, Morita H, Kigure W, Kato T, Yamauchi H, Suto T, Asao T, Kuwano H.

Hepatogastroenterology. 2012 Nov-Dec;59(120):2477-9. doi: 10.5754/hge10295.

PMID:
23169180
5.

Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery.

Sasaki S, Miyakoshi N, Matsuura H, Saito H, Nakanishi T, Kudo Y, Fujiya T, Shimada Y.

J Orthop Sci. 2011 Jan;16(1):64-70. doi: 10.1007/s00776-010-0011-5.

PMID:
21293896
6.

Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.

Eriksson BI, Lassen MR; PENTasaccharide in HIp-FRActure Surgery Plus Investigators..

Arch Intern Med. 2003 Jun 9;163(11):1337-42.

PMID:
12796070
7.

Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.

Mismetti P, Samama CM, Rosencher N, Vielpeau C, Nguyen P, Deygas B, Presles E, Laporte S; PROPICE Study Group..

Thromb Haemost. 2012 Jun;107(6):1151-60. doi: 10.1160/TH11-09-0640.

PMID:
22476471
8.
9.

Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery.

Sasaki S, Miyakoshi N, Matsuura H, Saitoh H, Kudoh D, Shimada Y.

J Orthop Sci. 2009 Sep;14(5):491-6. doi: 10.1007/s00776-009-1365-4.

PMID:
19802659
10.

Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study.

Lu JP, Knudson MM, Bir N, Kallet R, Atkinson K.

J Am Coll Surg. 2009 Nov;209(5):589-94. doi: 10.1016/j.jamcollsurg.2009.08.001.

PMID:
19854398
11.

Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.

Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M; PEGASUS investigators..

Br J Surg. 2005 Oct;92(10):1212-20.

PMID:
16175516
12.

Safety of fondaparinux in the prevention of venous thromboembolism in elderly medical patients: results of a single-center, retrospective study.

Silvestri F, Pasca S, Labombarda A, Barbi A, Desideri M, Guidi P, Rogato A, Zaramella M, Bergamo M, Ageno W, Barillari G.

Minerva Med. 2014 Jun;105(3):221-8.

PMID:
24988087
13.

Plasma accumulation of fondaparinux 2.5 mg in patients after total hip arthroplasty.

Yukizawa Y, Inaba Y, Watanabe S, Yajima S, Kobayashi N, Ishida T, Iwamoto N, Hyonmin C, Nakamura M, Saito T.

J Thromb Thrombolysis. 2012 Nov;34(4):526-32. doi: 10.1007/s11239-012-0773-z.

PMID:
22802080
14.

Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.

Beyer-Westendorf J, Lützner J, Donath L, Radke OC, Kuhlisch E, Hartmann A, Weiss N, Werth S.

J Thromb Haemost. 2012 Oct;10(10):2045-52. doi: 10.1111/j.1538-7836.2012.04877.x.

15.

Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery.

Kulik A, Rassen JA, Myers J, Schneeweiss S, Gagne J, Polinski JM, Liu J, Fischer MA, Choudhry NK.

Circ Cardiovasc Interv. 2012 Aug 1;5(4):590-6. doi: 10.1161/CIRCINTERVENTIONS.112.968313.

16.

Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study.

Ageno W, Riva N, Noris P, Di Nisio M, La Regina M, Arioli D, Ria L, Monzani V, Cuppini S, Lupia E, Giorgi Pierfranceschi M, Dentali F; FONDAIR study group..

J Thromb Haemost. 2012 Nov;10(11):2291-7. doi: 10.1111/j.1538-7836.2012.04908.x. Erratum in: J Thromb Haemost. 2016 Jan;14(1):225. Pierfranceschi, M G [corrected to Giorgi Pierfranceschi, M].

17.
18.

Comparison of fondaparinux with low molecular weight heparin for venous thromboembolism prevention in patients requiring rigid or semi-rigid immobilization for isolated non-surgical below-knee injury.

Samama CM, Lecoules N, Kierzek G, Claessens YE, Riou B, Rosencher N, Mismetti P, Sautet A, Barrellier MT, Apartsin K, Jonas M, Caeiro JR, van der Veen AH, Roy PM; FONDACAST Study Group..

J Thromb Haemost. 2013 Oct;11(10):1833-43. doi: 10.1111/jth.12395.

19.

Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.

Tran AH, Lee G.

Ann Pharmacother. 2003 Nov;37(11):1632-43. Review.

PMID:
14565815
20.

The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study.

Singelyn FJ, Verheyen CC, Piovella F, Van Aken HK, Rosencher N; EXPERT Study Investigators..

Anesth Analg. 2007 Dec;105(6):1540-7, table of contents.

PMID:
18042845

Supplemental Content

Support Center